ArticleRare tumors2026
Chronic myeloid leukemia presenting with isolated central nervous system lymphoid blast crisis: A case report.
Article in Rare tumors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm driven by the Philadelphia chromosome, typically progressing through chronic, accelerated, and blast phases. Blast crisis may be myeloid or lymphoid. Isolated central nervous system (CNS) involvement is rare and represents a diagnostic and therapeutic challenge. Case presentation: We report a 40-year-old man with no prior hematologic history who presented with four months of progressive lower-limb paresthesias, neuropathic pain, and subacute weakness impairing ambulation. Neurologic examination revealed asymmetric paraparesis, hyporeflexia, and distal hypoesthesia in a stocking distribution, consistent with a subacute asymmetric sensorimotor polyradiculoneuropathy. Complete blood count demonstrated marked leukocytosis with neutrophilia, left shift, and circulating blasts. Contrast-enhanced spinal magnetic resonance imaging showed extensive leptomeningeal enhancement. Cerebrospinal fluid (CSF) analysis revealed pleocytosis, hypoglycorrhachia, and elevated protein levels; flow cytometry identified 14% B-lymphoid blasts (CD34+, CD19+, CD20+, CD22+). Bone marrow aspirate and biopsy showed hypercellularity with trilineage hematopoiesis, basophilia, and small hypolobated megakaryocytes, without a significant increase in blasts (<5%). Cytogenetic analysis identified t (9; 22), and molecular testing confirmed the BCR::ABL1 p210 transcript, consistent with chronic-phase CML. An isolated CNS lymphoid blast crisis was diagnosed. Treatment with HyperCVAD (Block B only) plus dasatinib 140 mg daily resulted in neurologic improvement and hematologic normalization. After five cycles, CSF clearance was achieved, followed by consolidation with haploidentical allogeneic hematopoietic stem cell transplantation. The patient remains in complete remission. Conclusions: Isolated CNS blast crisis may represent the initial manifestation of CML. Prompt recognition through integrated neurologic, hematologic, and molecular evaluation is critical to enable timely, targeted therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.